Antibiotic Microbiome Articles & Analysis
4 news found
Often associated with intestinal microbiome disruption, or “dysbiosis,” rCDI treatment standard of care is currently antibiotics, which is also a predominant risk factor for recurrence. ...
The clinical development program for RBX2660 is the most advanced in the world in evaluating the safety and efficacy of a standardized, non-antibiotic microbiome-based therapy. RBX2660 is being developed to reduce C. diff infection recurrences, an urgent unmet need for patients and healthcare providers worldwide. Antibiotics, the current ...
MedBiome’s founders reported in Microbiome the development of the RapidAIM platform to screen compounds against individual microbiomes in vitro. They tested 43 compounds (including 4 antibiotics) against 5 individual microbiomes using the RapidAIM technology. The RapidAIM workflow provides insights into ...
Today, MetaboGen and BioGaia have agreed to initiate a new development program addressing restoration of the microbiome after antibiotic treatment. The program will combine expertise and experience from both companies and is part of the long-term relationship between MetaboGen and BioGaia. ...